belatacept - Nulojix; BMS-224818; CTLA4-Ig mutant; cytotoxic T-lymphocyte- associated antigen 4 ((CTLA-4)--Immunoglobulin G1 fragment fusion protein, recombinant -- Product Record

CTLA4-Ig, rDNA/belatacept

    Nomenclature:
      CTLA4-Ig, rDNA/belatacept [BIO]
      Nulojix [TR]
      belatacept [USAN; INN]
      CTLA-4 (antigen) [29-tyrosine, 104-glutamic acid] (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 ·human monoclonal Fc domain-containing fragment bimol. (12--->120')-disulfide [CAS]
      [Tyr29,Glu104,Gln125,Ser130,Ser136,Ser139,Ser148](antigen CTLA-4 human-3-126]-peptide (fragment containing the human extracellular domain) fusion protein with immunoglobulin G1-[233 amino acids from the C-terminal of the heavy chain]-peptide (fragment containing the human monoclonal Fc domain), bimolecular (120→120')-disulfide [CAS]
      706808-37-9 [CAS RN]
      [29-tyrosine, 104-glutamic acid] (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 (human monoclonal Fc domain-containing fragment, bimol. (120-->120')-disulfide [SY]
      BMS-224818 [SY]
      BMS224818 [SY]
      CTLA4-Ig mutant [SY]
      L104EA29YIg [SY]
      LEA [SY]
      LEA29Y [SY]
      NDC 0003-0371-13 [NDC]

    molecular weight (kDa) = 91.5

    FDA Class:  Biologoic BLA

    Year of approval (FDA) = 2011